Fig. 5

Attrition diagram for rheumatoid arthritis (RA); patient attrition counts and proportions after sequential design choices applied in the Optum® EHR database
Key – Target: patients with RA newly exposed to Remicade®, Comparator: patients with RA newly exposed to golimumab, certolizumab pegol, ustekinumab, vedolizumab]